Clinical Trials · NCT04760691
Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Johns Hopkins University
- Enrollment
- 13
- Start date
- Mar 2021
- Locations
- 1 site, United States
- Primary endpoint
- Change in Maximum Tenofovir Plasma (Cmax) Concentration